Mounjaro vs Wegovy: UK Prescriber-Guided Comparison
Compare Mounjaro and Wegovy: Mechanism and Active Ingredient Analysis
When you compare Mounjaro and Wegovy, the fundamental difference lies in their active ingredients and receptor targeting mechanisms. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics the natural incretin hormone to promote satiety and reduce appetite through brain appetite centres. Mounjaro contains tirzepatide, a dual-action medication that targets both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors simultaneously. This dual mechanism may offer different metabolic effects, though both treatments work to support weight management when prescribed alongside lifestyle modifications. The choice between these prescription-only medicines ultimately depends on individual patient factors that qualified prescribers assess during clinical evaluation.
Both medications require weekly subcutaneous injections using pre-filled pen devices, making the practical administration similar regardless of which treatment your prescriber recommends. The injection technique, pen handling, and disposal methods follow identical protocols, ensuring patients can transition between treatments if clinically appropriate. However, the dose escalation schedules differ significantly, with Wegovy following a structured 16-week escalation to maintenance dosing, whilst Mounjaro utilises a different titration approach. Understanding these practical differences helps patients prepare for their chosen treatment journey and set realistic expectations for the initial months of therapy.
Wegovy vs Mounjaro Pricing: UK Online Pharmacy Costs Compared
EverydayMeds offers transparent pricing for both treatments, allowing patients to compare Mounjaro and Wegovy costs when making their decision. Wegovy pricing starts at £79.99 for the 0.25mg starter dose (after FIRST40 discount for new customers), progressing through £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg), to £209.99 for the 2.4mg maintenance dose. Our convenient bundle options include the Intro Duo (0.25mg & 0.5mg) for £169.99 and the Progress Trio (0.5mg, 1mg & 1.7mg) for £369.99, providing structured dose escalation packages. Returning customers benefit from the DOSE25 code applied at checkout, whilst new patients use FIRST40 to reach these final prices.
Mounjaro pricing follows its own structure reflecting the different dose strengths and escalation schedule, with both treatments requiring ongoing prescription costs throughout the maintenance phase. When patients compare Mounjaro and Wegovy financially, consideration should include the total treatment duration, potential need for long-term therapy, and individual response rates. Our clinical team can discuss cost-effectiveness based on patient-specific factors during the assessment process, ensuring financial considerations align with clinical appropriateness. Both medications represent significant investment in health improvement, requiring careful budgeting for sustainable long-term weight management success.
Clinical Evidence: When You Compare Mounjaro and Wegovy Trial Data
The clinical evidence base for both treatments demonstrates substantial efficacy in supporting weight management, though direct head-to-head comparisons remain limited due to different trial designs and patient populations. Wegovy's evidence stems primarily from the STEP trial programme, including STEP 1 which showed approximately 15% average weight loss at 68 weeks alongside diet and exercise interventions (Wilding et al., NEJM, 2021). The STEP 2 trial specifically evaluated patients with type 2 diabetes, demonstrating approximately 9.6% weight reduction, whilst STEP 5 confirmed sustained benefits at two years.
Mounjaro's clinical programme utilised different endpoints and methodologies, making direct percentage comparisons inappropriate between the two treatments. Both medications demonstrated statistically significant weight loss compared to placebo groups in their respective trials, with results consistently superior to lifestyle modification alone. Patients should understand that clinical trial results represent average outcomes in controlled settings, and individual responses may vary significantly based on adherence, lifestyle factors, and underlying health conditions.
How Wegovy Works: GLP-1 Mechanism for Weight Management
Wegovy functions as a GLP-1 receptor agonist, mimicking the action of glucagon-like peptide-1, a naturally occurring incretin hormone that regulates appetite and food intake. When administered weekly via subcutaneous injection, semaglutide binds to GLP-1 receptors in the brain's appetite control centres, promoting feelings of satiety and reducing hunger signals between meals. This mechanism may help patients feel satisfied with smaller portions and experience reduced food cravings, particularly for high-calorie foods that often contribute to weight gain. The medication also slows gastric emptying, prolonging the feeling of fullness after eating and supporting adherence to reduced-calorie dietary plans. Unlike rapid-acting appetite suppressants, Wegovy provides sustained appetite regulation throughout the week, supporting consistent eating pattern modifications essential for long-term weight management success.
Ordering Process: Compare Mounjaro and Wegovy Online Assessment
EverydayMeds streamlines the ordering process for both treatments through our comprehensive online clinical assessment, completed in approximately three minutes covering medical history, current medications, and weight management goals. Following submission, our qualified prescribers review applications within three working days (or 24 hours with express service), evaluating suitability for either Wegovy or Mounjaro based on individual patient factors and clinical guidelines. Once approved, medications are dispatched via next-day delivery using temperature-controlled cold-chain logistics to ensure product integrity throughout transport. Our GPhC-registered pharmacy (#9012878) ensures full regulatory compliance and authentic medication supply, with ongoing prescriber support available throughout treatment. Patients receive detailed injection training materials, dose escalation schedules, and access to our clinical team for any treatment-related queries during their weight management journey.
Storage and Practical Considerations: Mounjaro vs Wegovy Comparison
Storage requirements present one practical advantage when you compare Mounjaro and Wegovy for UK patients, particularly those with active lifestyles or frequent travel commitments. Wegovy maintains stability for up to six weeks at room temperature (below 30°C) once removed from refrigeration, compared to Mounjaro's 21-day room temperature limit, providing greater flexibility for holidays, business travel, or temporary refrigeration disruptions. Both medications require initial storage at 2-8°C in the refrigerator and utilise similar pre-filled pen injection systems with equivalent disposal requirements. The FlexTouch pen design (Wegovy) and comparable pen system (Mounjaro) offer user-friendly injection experiences with clear dose markings and safety features. Patients should plan injection schedules around the same weekly day and time, regardless of chosen treatment, ensuring consistent medication levels and optimal therapeutic response throughout the escalation and maintenance phases.
UK Regulatory Status: Compare Mounjaro and Wegovy MHRA Licensing
Both treatments hold MHRA marketing authorisation for weight management in adults with BMI ≥30 kg/m², or BMI ≥27 kg/m² with weight-related comorbidities, ensuring equivalent regulatory approval for UK prescribing. NICE guidance (TA875) recommends Wegovy within specialist weight management services, whilst Mounjaro evaluation continues through established NICE processes for weight management indications. When patients compare Mounjaro and Wegovy regulatory status, both carry Black Triangle (▼) additional monitoring symbols, indicating new medicines requiring enhanced adverse event reporting to support ongoing safety surveillance.
EverydayMeds operates under GPhC registration (#9012878), ensuring both medications meet stringent pharmacy standards for storage, handling, and patient safety throughout the supply chain. Our prescribers assess eligibility based on current MHRA-approved indications, ensuring appropriate patient selection regardless of which treatment proves more suitable for individual circumstances. Regulatory equivalence means patients can focus on clinical and practical factors when choosing between treatments, confident that both options meet identical UK safety and efficacy standards for prescription-only medicine classification.
Expert Prescriber Assessment: Choosing Between Wegovy and Mounjaro
Professional clinical assessment remains essential when you compare Mounjaro and Wegovy, as individual patient factors significantly influence treatment selection beyond mechanism differences or pricing considerations. Our qualified prescribers evaluate medical history, current medications, previous weight management attempts, and specific health goals to recommend the most appropriate treatment option for each patient. Factors including injection frequency preferences, storage requirements, potential drug interactions, and existing medical conditions all contribute to personalised treatment recommendations that maximise therapeutic success whilst minimising potential risks. Both Wegovy and Mounjaro are available from EverydayMeds, allowing our prescribers flexibility to choose the optimal treatment based on comprehensive patient assessment rather than limited formulary options. This personalised approach ensures treatment selection aligns with individual lifestyles, medical needs, and long-term weight management objectives for sustained success beyond initial weight loss phases.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
